ArriVent BioPharma (AVBP) Q1 2026 earnings summary

Executive summary

• Focused on developing and commercializing differentiated oncology medicines, with lead candidate firmonertinib in multiple Phase 3 trials for EGFR-mutant NSCLC and ARR-217 in Phase 1 for solid tumors.

• Advanced pivotal Phase 3 trials for firmonertinib in first-line EGFR exon 20 insertion mutant NSCLC, with topline data expected mid-2026.

• Received FDA Breakthrough Therapy and Orphan Drug Designations for firmonertinib and accelerated approval in China for second-line EGFR exon 20 insertion mutant NSCLC.

• IND clearance for ARR-002, a dual-target ADC, with first patient dosing planned for 2H 2026 in ovarian and endometrial cancers.

• Presented preclinical data at AACR showing superior anti-tumor activity for ARR-002 and structural advantages for firmonertinib.

Financial highlights

• Net loss of $43.3 million for Q1 2026, down from $64.4 million in Q1 2025, driven by lower R&D expenses.

• Operating expenses were $46.1 million, with R&D at $37.6 million and G&A at $8.5 million for Q1 2026.

• Interest and investment income increased to $2.8 million from $2.4 million year-over-year.

• Cash, cash equivalents, and marketable securities totaled $326.4 million as of March 31, 2026, expected to fund operations into Q4 2027.

• Net cash used in operations was $41.9 million for Q1 2026, compared to $68.0 million for Q1 2025.

Outlook and guidance

• Expects continued operating losses as clinical and preclinical programs advance.

• Topline Phase 3 data for firmonertinib in first-line EGFR exon 20 insertion mutant NSCLC expected mid-2026.

• First patient dosing for ARR-002 in Phase 1 trial planned for 2H 2026; Phase 1 dose optimization for ARR-217 to begin in 2H 2026.

• Current liquidity expected to fund operations for at least 12 months from the reporting date; cash runway projected into Q4 2027.

• Plans to seek additional funding through equity, debt, or partnerships as needed.